Evidence map›Paper›PMID 35523996›Full record

ArticleJournal of community genetics2022

Co-designing models for the communication of genomic results for rare diseases: a comparative study in the Czech Republic and the United Kingdom.

Alessia Costa, Věra Franková, Glenn Robert, Milan Macek, Christine Patch, Elizabeth Alexander, Anna Arellanesova, Jill Clayton-Smith, Amy Hunter, Markéta Havlovicová and 5 more

Erratum issuedAbstract read
In one paragraph

Article in Journal of community genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Alessia CostaEngagement and Society, Wellcome Connecting Science, Hinxton, CB10 1SA, Cambridgeshire, UK. alessia.costa@wellcomeconnectingscience.org.
Věra FrankováDepartment of Paediatrics and Inherited Metabolic Disorders, Charles University, First Faculty of Medicine and General University Hospital, Prague, Czech Republic. vera.frankova@lf1.cuni.cz.ORCID http://orcid.org/0000-0002-1927-9596
Glenn RobertFaculty of Nursing, Midwifery and Palliative Care, King's College London, London, SE1 8WA, UK.
Milan MacekDepartment of Biology and Medical Genetics, Charles University, Second Faculty of Medicine, and University Hospital Motol, Prague, Czech Republic.
Christine PatchEngagement and Society, Wellcome Connecting Science, Hinxton, CB10 1SA, Cambridgeshire, UK.
Elizabeth AlexanderManchester Centre For Genomic Medicine, University of Manchester, St Mary's Hospital, Manchester, M13 9WL, UK.
Anna ArellanesovaČeská asociace pro vzácná onemocnění (ČAVO), Rare Diseases Czech Republic, Bělohorská 19, Praha 6, 169 00, Czech Republic.
Jill Clayton-SmithManchester Centre For Genomic Medicine, University of Manchester, St Mary's Hospital, Manchester, M13 9WL, UK.
Amy HunterGenetic Alliance UK, London, EC2A 4NE, UK.
Markéta HavlovicováDepartment of Biology and Medical Genetics, Charles University, Second Faculty of Medicine, and University Hospital Motol, Prague, Czech Republic.
Radka PourováDepartment of Biology and Medical Genetics, Charles University, Second Faculty of Medicine, and University Hospital Motol, Prague, Czech Republic.
Marie PritchardSyndromes Without A Name (SWAN UK), London, EC2A 4NE, UK.
Lauren RobertsGenetic Alliance UK, London, EC2A 4NE, UK.
Veronika ZoubkováDepartment of Biology and Medical Genetics, Charles University, Second Faculty of Medicine, and University Hospital Motol, Prague, Czech Republic.
Alison MetcalfeZinc Ventures, London, UK.

Funding

Horizon 2020 779257Ministerstvo Školství, Mládeže a Tělovýchovy LM2018132Ministerstvo Zdravotnictví Ceské Republiky 00064203/6003
6 · The paper itself

Abstract

The communication of genomic results to patients and families with rare diseases raise distinctive challenges. However, there is little evidence about optimal methods to communicate results to this group of service users. To address this gap, we worked with rare disease families and health professionals from two genetic/genomic services, one in the United Kingdom and one in the Czech Republic, to co-design that best meet their needs. Using the participatory methodology of Experience-Based Co-Design (EBCD), we conducted observations of clinical appointments (n=49) and interviews with family participants (n=23) and health professionals (n=22) to gather their experience of sharing/receiving results. The findings informed a facilitated co-design process, comprising 3 feedback events at each site and a series of meetings and remote consultations. Participants identified a total of four areas of current service models in need of improvement, and co-designed six prototypes of quality improvement interventions. The main finding was the identification of post-test care as the shared priority for improvement for both health professionals and families at the two sites. Our findings indicate the need to strengthen the link between diagnostics (whether or not a pathogenic variant is found) and post-test care, including psychosocial and community support. This raises implications for the reconfigurations of genomic service models, the redefinition of professional roles and responsibilities and the involvement of rare disease patients and families in health care research.

Indexed as

Experience-based co-designGenetic servicesGenomic testingPatient involvementRare diseases

Identifiers

PMID35523996
PMCPMC9075921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.